Extracorporal Photopheresis Pilot Study

Inclusion Criteria: * Patients ≥ 18 years and \< or = 65 years with an hematological malignancy indicated for an allogeneic transplantation after reduced intensity conditioning : * due to the age : for patients between 55 and 65 years. * or for patients between 18 and 55 years of age presenting a risk of increased toxicity for myeloablative conditioning (cardiac, renal or pulmonary pathology) * CML and MPS in blastic phase achieving CR, * MM stage II or III, relapse after autologous transplant, achieving a response ≥ 30% or on first line if high risk, * NHL in 2nd CR, PR after chemotherapy or autologous transplant, chemo-sensible. * CLL in 2nd CR, PR after chemotherapy or autologous transplant, chemo-sensible. * AML in 2nd CR or in first line for high risk criteria, secondary AML. In AML, high risk criteria are defined by : LAM 7, leukocytes\>30000/mm3, cytogenetic abnormalities: t(6,9); 11q23, 17p, 11q, 20q, 21q, -5, del(5q), -7/del7q, del 9q and inv 3q, * ALL in 2nd CR or in first line for high risk criteria defined by cytogenetic abnormalities: 11q23, t(9,22); t(1,19); t(4,11). * MDS patients without prior chemotherapy * HLA identical sibling donor * Performans status \< or = 2 * Patients member of a social security company Exclusion Criteria: * Age \< 18 years or \> 65 years * Pregnant or lactating females * Known HIV positivity * Active infectious hepatitis, type A, B or C * Performance status \> 2 according to WHO * Left ventricular ejection fraction \< 40% and Alveolus-capillary diffusion \< 50% * Uncontrollable hypertension with medical therapy * Creatinine clearance \< 60 ml/min * Hypersensitivity or allergy to psoralen (methoxsalen) * Disease associated with a photosensitivity * Hypersensitivity or allergy to both heparin and citrate products * Contra-indication to Busulfan, Fludarabine, SAT or methotrexate * Hypersensitivity to ciclosporine, mycophenolate mofetil or mycophenolic acid